The Longest Day 2018
Home | News | Events | Press | Contact  

About UseNewsletterMessage BoardsAction CenterAdvocateWalk to End Alzheimer’sShopDonate

Find your chapter:

search by state

In My Community

Weekly e-news

We will not share your information.

Text Size controlsNormal font sizeMedium font sizeLarge font size

Facts and Figures

Alzheimer's disease is the 6th leading cause of death in the United States. View local facts and figures related to the staggering statistics of Alzheimer's disease and other dementias in Indiana. National statistics are also available.

Local Research

Alzheimer's Association partners with Indiana University in younger-onset Alzheimer's study funded by NIH
A new research study promises to yield valuable insights by focusing on individuals who develop Alzheimer's disease before age 65. Principal investigator Liana G. Apostolova, M.D., and her team at the Indiana University School of Medicine, were awarded a one-year, $7.6 million grant from the National Institute of Health (NIH) to establish a network of sites to study the disease’s onset and progression in Longitudinal Early-Onset Alzheimer’s Disease Study (LEADS).  

Working with the Alzheimer’s Association, research cores and clinical sites at 16 institutions nationwide, the team will build a network of qualified individuals who are willing to participate in this study. Over a number of years, they will collect robust clinical and biomarker data from a large cohort of people whose younger-onset disease, like the majority of all Alzheimer’s cases, is not caused by dominantly inherited genetic mutations.  

The NIH grant allows Dr. Apostolova and co-principal investigators Maria Carillo, Ph.D., Alzheimer’s Association; Brad Dickerson, M.D., Harvard University; and Gil Rabinovici, M.D., University of California, to establish infrastructure and recruitment for an approximately $45 million research program.  

More information about LEADS will be available in the coming weeks.


Alzheimer's Association Awards Grant to Indiana University Scientist
In vivo analysis of cell-type-specific expression of Tau and Tau spreading

The Alzheimer's Association announced a 2017 Zenith Fellows Award to Ruben Vidal, Ph.D., Indiana University, for $450,000 over three years. Tau is a protein that normally helps to maintain nerve cell structure and transport nutrients throughout the cell. In Alzheimer's disease, tau becomes abnormally modified and can form tau tangles in the brain, a hallmark of the disease. Recent evidence suggests that abnormal tau protein can spread from one nerve cell to the next, possibly contributing to the progression of brain changes associated with Alzheimer's disease. However, the mechanisms that underlie the accumulation and movement of abnormal tau in the brain are not well understood. 

Dr. Vidal’s laboratory research uses genetically engineered mice in which tau protein is lacking in their nerve cells or support cells (also called astrocytes) within the brain. A series of experiments is conducted by placing abnormal human tau protein into the engineered mice, then removing tau from either nerve or support cells and measuring the spread of tau protein and changes in memory function over a series of months.

The results of this study could identify which types of brain cells may contribute to the accumulation and spread of abnormal tau and could possibly identify new targets for drug treatments aimed at blocking the spread of abnormal tau protein to help slow or prevent disease progression.

TrialMatch Survey: Dr. Apostolova, Indiana Alzheimer Disease Center 
Amyloid PET Questionnaire for Person with Memory Loss, Early Stage Dementia, FTD, and/or their Caregivers

Indiana researcher and member of the Alzheimer's Association Medical & Scientific Advisory Council Liana Apostolova, M.D., has a study available through TrialMatch®, our free, easy-to-use clinical studies matching service that connects individuals with Alzheimer's, caregivers, healthy volunteers and physicians with current studies. The purpose of this study is to obtain the thoughts and feelings of individuals who might be interested in receiving an amyloid PET and use that data to apply for research grant funding. They are actively recruiting 500 participants.

We need your input and advice as we think about a developing a research project to assess the use of Amyloid PET imaging. This type of neuroimaging has been FDA approved for some time; yet insurance companies do not cover the cost of this type of scan because it is not certain whether such information will have an impact on patient care. Thus, doctors do not order this test.

Eligibility: You or the person you care for have memory loss or early-stage dementia
Cost: Free; register through TrialMatch
Time Commitment: 2-5 minutes, 7 questions
Confidentiality: Anonymous, no personal information is collected.

To learn more or to participate in Dr. Apostolova's study, click here.

What is amyloid imaging? Read more here.




Alzheimer's Association

Our vision: A world without Alzheimer's disease®.
Formed in 1980, the Alzheimer's Association is the world's leading voluntary health organization in Alzheimer's care, support and research.